Trials / Completed
CompletedNCT02575222
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Phase I Study of Neoadjuvant Nivolumab in Patients With Non-metastatic High-risk Clear Cell Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the use of nivolumab before surgery in patients with high-risk clear cell renal cell carcinoma who are eligible for nephrectomy. Nivolumab is an antibody that may help activate the immune system by blocking the function of an inhibitory molecule, Programmed cell death-1 (PD-1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | 3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy. |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2020-06-09
- Completion
- 2020-06-09
- First posted
- 2015-10-14
- Last updated
- 2020-06-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02575222. Inclusion in this directory is not an endorsement.